A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 May 2016 Data from this trial will be presented at the Society of Investigative Dermatology's (SID) 2016 SID Annual Meeting, according to an Amics Therapeutics media release.
26 Feb 2016 Data from this trial will be presented at the American Academy of Dermatology's Annual Meeting 2016, according to an Amicus Therapeutics media release.
02 Sep 2015 According to Amicus Therapeutics media release, allantoin [SD 101; Zorblisa] has received breakthrough designation from US FDA based on phase II data.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com